Crystalline 4-(Ethylsulfonyloxy)-DPT Chloride for Accurate Drug Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to obtain and characterize crystalline forms of tryptamine and psychedelic drug compounds to improve their chemical and physical properties, ensuring accurate molecular weight determination and reducing errors in drug dosing and potency calculations.
Innovation Solution
The development of specific crystalline forms of 4-(ethylsulfonyloxy)-DPT chloride, TPT iodide, 5-Cl-DiPT iodide, 5-Cl-T hydrogenoxalate, and 5-Cl-T oxalate hydrate, characterized by unique X-ray powder diffraction patterns and space groups, which are used in pharmaceutical compositions to regulate neurotransmitter activity and treat conditions such as psychological disorders and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If crystalline forms of tryptamine and psychedelic drug compounds are obtained and characterized, then molecular weight determination accuracy is improved and dosing errors are reduced, but the complexity of chemical characterization and crystal structure determination increases
Solution Approach 1:
The patent changes the physical state parameter of the compounds from amorphous to crystalline forms. This parameter change enables accurate molecular weight determination through crystal structure determination, as the ordered arrangement in crystalline states provides definitive data for calculating molecular weight, thereby resolving the measurement accuracy issue while the characterization complexity is managed through standard crystallographic methods
2Reliability
If crystalline forms with specific space groups and X-ray powder diffraction patterns are developed, then pharmaceutical and pharmacological properties are improved, but the manufacturing process complexity increases
Solution Approach 1:
The patent performs preliminary crystallization actions during the drug development stage to establish specific crystalline forms with desired pharmaceutical properties. By determining the optimal crystalline structure early in development, the manufacturing process can be designed around this established form, reducing complexity during scale-up production while maintaining the reliability benefits of the crystalline structure
Solution Approach 2:
The patent utilizes phase transition from amorphous to crystalline states to improve pharmaceutical properties. The specific space groups and X-ray powder diffraction patterns indicate controlled phase transitions that enhance stability, solubility, and bioavailability. These phase transitions are incorporated into the manufacturing process to produce the desired crystalline forms without excessive complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystalline forms provide improved pharmaceutical and pharmacological properties, enabling precise molecular weight determination and effective treatment of psychological disorders, inflammation, and other conditions by regulating neurotransmitter activity.
Implementation Method 1
characterized by unique X-ray powder diffraction patterns and space groups
Implementation Method 2
X-ray powder diffraction patterns
Data Source
AI summary
This disclosure relates to (2-{4-[ethanesulfonyl)oxy]-1H-indol-3-yl}ethyl)dipropylazanium chloride (4-(ethylsulfonyloxy)-N,N-di-n-propyltryptammonium chloride or 4-(ethylsulfonyloxy)-DPT chloride), crystalline 4-(ethylsulfonyloxy)-DPT chloride, [2-(1H-indol-3-yl)ethyl]tripropylazanium iodide (N,N,N-tri-n-propyltryptammonium iodide or TPT iodide), crystalline TPT iodide, [2-(5-chloro-1H-indol-3-yl)ethyl]bis(propan-2-yl)azanium iodide (5-chloro-A/,A/-di-n-isopropyltryptammonium iodide or 5-CI-DiPT iodide), crystalline 5-CI-DiPT iodide, 2-(5-chloro-1H-indol-3-yl)ethan-1-aminium hydrogen oxalate (5-chlorotryptammonium hydrogenoxalate or 5-CI-T hydrogenoxalate), crystalline 5-CI-T hydrogenoxalate, bis(2-(5-chloro-1H-indol-3-yl)ethan-1-aminium) dihydrate oxalate (5-chlorotryptammonium oxalate hydrate or 5-CI-T oxalate hydrate), crystalline 5-CI-T oxalate hydrate, and specific crystalline forms thereof, including crystalline form 1 of 4-(ethylsulfonyloxy)-DPT chloride, crystalline form 1 of TPT iodide, crystalline form of 1 of 5-CI-DiPT iodide, crystalline form 1 of 5-CI-T hydrogenoxalate, and crystalline form 1 of 5-CI-T oxalate hydrate, to compositions containing the same, and to methods of treatment using the.